X
X
Close
Close

Colourfree Baby Drops 1-2 Months

Close

Colourfree Suspension 1-5 Years

Close

Chewable Tablets 3+

Close

Suppositories 6 Months - 5 Years

Close

Colourfree Suspension 5-12 Years

Close

Elixir 5 - 12 Years

Close

Suppositories 5-12 Years

Close

Soluble 7+

Close

Panadol Tablets

Close

Panadol Caplets with Optizorb Formulation

Close

Panadol Tablets with Optizorb Formulation

Close

Panadol Mini Caps

Close

Panadol Suppositories

Close

Panadol Extra Caplets

Close

Panadol Rapid Soluble

Close

Panadol Rapid Caplets

Close

Panado Rapid Handipak

Close

Panadol Osteo

Close

Panadol Cold & Flu + Decongestant

Close

Panadol Cold & Flu - Flu Strength (Day & Night)

Close

Panadol Cold & Flu Relief + Cough

Close

Panadol Cold & Flu MAX Hot Lemon

Close
Panadol Colour-Free Baby Drops 1-2 Years

Colourfree Baby Drops 1 Month - 1 Year

  • Concentrated Drops
  • 1 Month - 1 Years
  • Gentle on Tiny Tummies
  • 500mg Paracetamol
    No gluten, lactose or sugar
Close
panadol colour-free suspension 5-12 years

Colourfree Suspension 1-5 Years

  • Suspension
  • 1-5 Years
  • Strawberry/Orange Flavour
  • Active Ingredient: Paracetamol 24 mg/mL
Close
Panadol Chewable Tablets

Chewable Tablets 3+

  • Dissolvable Tablets
  • 1-5 Years
  • Perfect For Travel
  • Active Ingredient: 120mg of Paracetamol per tablet
Close
Panadol Suppositories 6months-5years

Suppositories 6 Months - 5 Years

  • Suppositories
  • 6 Months - 5 Years
  • For vomiting
  • Active ingredient: Paracetamol 125mg per suppository.
Close
panadol colour-free suspension 1-5 years

Colourfree Suspension 5-12 Years

  • Suspension
  • 5-12 Years
  • Strawberry/Orange Flavour
  • Active ingredient: Paracetamol 48 mg/mL
Close
Panadol Elixir 5-12 Years

Elixir 5 - 12 Years

  • Suspension
  • 5-12 Years
  • Fast & gentle relief
  • Active ingredient: Paracetamol 48 mg/mL
Close
Panadol Suppositories 5-12 Years

Suppositories 5-12 Years

  • Suppositories
  • 5-12 Years
  • For vomiting
  • Active ingredient: 250mg Paracetamol per suppository
Close
Panadol Soluble 7+

Soluble 7+

  • Effervescent Tablets
  • 7+ Years
  • Absorbed quicker
  • Active ingredient: Paracetamol
Close
Panadol Tablets

Panadol Tablets

  • Tablets
  • 12+ Years
  • Basic Pain
  • Active ingredient: 500mg Paracetamol
Close
Panadol Caplets With Optizorb Formulation

Panadol Caplets with Optizorb Formulation

  • Caplets
  • 12+ Years
  • Quicker Absorbtion
  • Active ingredient: 500mg Paracetamol
Close
Panadol Tablets With Optizorb Formulation

Panadol Tablets with Optizorb Formulation

  • Tablets
  • 12+ Years
  • Quicker Absorbtion
  • Active ingredient: 500mg Paracetamol
Close
Panadol Mini Caps

Panadol Mini Caps

  • Caplets
  • 12+ Years
  • Easier to swallow
  • Active ingredient: 500mg Paracetamol
Close
Panadol Suppositories

Panadol Suppositories

  • Suppositories
  • 12+ Years
  • For vomiting
  • Active ingredient: 500mg Paracetamol per suppository.
Close
Panadol Extra

Panadol Extra Caplets

  • Caplets
  • 12+ Years
  • Fight Tough Pai
  • Active ingredient: 500mg Paracetamol , 65mg caffeine
Close
Panadol Rapid Handipak

Panadol Rapid Soluble

  • Dissolvable Tablets
  • 12+ Years
  • Absorbed 2x Faster
  • Active ingredient: 500mg Paracetamol
Close
Panadol Rapid Caplets

Panadol Rapid Caplets

  • Caplets
  • 12+ Years
  • Absorbed 2x Faster
  • Active ingredient: Paracetamol
Close
Panadol Rapid Handipak

Panado Rapid Handipak

  • Caplets
  • 12+ Years
  • Absorbed 2x Faster
  • Active ingredient: 500mg Paracetamol
Close
Panadol Osteo

Panadol Osteo

  • Tablets
  • 12+ Years
  • Up to 8 hours
  • Active ingredient: 665mg Paracetamol
Close
Panadol Cold & Flu + Decongestant

Panadol Cold & Flu + Decongestant

  • Caplets
  • 12+ Years
  • With Decongestant
  • 500mg Paracetamol
Close
Panadol Cold And Flu Strength Day And Night

Panadol Cold & Flu - Flu Strength (Day & Night)

  • Caplets
  • 12+ Years
  • Day & Night Relief
  • 500mg Paracetamol
Close
Panadol Cold & Flu Relief + Cough

Panadol Cold & Flu Relief + Cough

  • Caplets
  • 12+ Years
  • Cough Relief
  • 500mg Paracetamol
Elderly couple piggy backing

The hidden burden of
osteoarthritis pain in Australia

The hidden burden of
osteoarthritis pain in Australia

The hidden burden of
osteoarthritis pain in Australia

Elderly couple piggy backing

The hidden burden of
osteoarthritis pain in Australia

Globally, osteoarthritis (OA) is the most frequent cause of disability in older adults, affecting up to 15% of individuals over 60 years of age.The prevalence and burden of OA is increasing worldwide, including in Australia, due to an ageing population and an increase in associated factors such as obesity.1,2 By 2030, OA is expected to affect 12% of the Australian population.2

OA is the most common form of chronic arthritis,2 and is characterised by a progressive, localised loss of joint cartilage—most commonly in the knees, hips, and hands—resulting in pain, inflammation and loss of joint mobility.2,3 Nearly three-quarters of individuals with OA report constant pain symptoms.1 The physical effects arising from OA pain and loss of functional ability can reduce quality of life, increase the chance of other morbidities,1,3 and can negatively impact work ability and productivity.2

Several risk factors are associated with development of OA, including genetics, overweight or obesity, older age, and joint injury.2,3 Generally, OA affects women more frequently than men.3

 

GLOBAL PAIN INDEX HIGHLIGHTS ATTITUDES TOWARDS OSTEOARTHRITIS PAIN IN AUSTRALIA1
Understanding the impact of osteoarthritis pain on personal and emotional wellbeing

The 2017 Global Pain Index (GPI) is a recent in-depth study commissioned by GSK Consumer Healthcare to look into attitudes towards physical pain, including OA pain, as well as the impact that
pain has on people’s lives around the world and how physical pain affects them at a macroeconomic level, as well as at a social and emotional level. The purpose of this study is to raise awareness of
what has become a hidden epidemic. The results not only help us to understand the true scale of the issue, but the many impacts that OA pain has on people who live with it.

According to the GPI study, OA pain affects 23% of people surveyed over the age of 18 years in Australia. In over 80% of respondents, OA pain adversely affects quality of life, with the majority of individuals with OA pain reporting an impact on their everyday activities, happiness, and sleep.

83% OF PEOPLE WITH OSTEOARTHRITIS PAIN IN AUSTRALIA SAY THAT OSTEOARTHRITIS PAIN DECREASES THEIR QUALITY OF LIFE 1

 

The GSK Global Pain Index (GPI) 2017 is a global study, commissioned by GSK Consumer Healthcare, looking into attitudes toward physical pain, and the impact that physical and OA pain has on people’s lives around the world. The study included over 19,000 people an used online interviews in 32 countries, including Australia, with people aged 18 and over.4

OSTEOARTHRITIS MANAGEMENT

A holistic approach is recommended for the assessment, diagnosis, and management of OA.2

 

Non-surgical management of knee and/or hip OA2

NSAIDs, non-steroidal anti-inflammatory drug.

 

COMORBIDITIES

Patients with OA are often older and with comorbidities, thereby increasing the likelihood of polypharmacy.5 Older patients take an average of 3–5 medications, increasing the risk of drug–drug
interactions and adverse events.20 Paracetamol has few drug–drug interactions and is generally suitable in polypharmacy.6 Paracetamol has excellent gastrointestinal tolerance7,8 and a very low risk of renal or hepatic side effects.8 However, paracetamol should be used with caution in patients with renal or hepatic impairment.6 As with all medications, patients using long-term, regular paracetamol should also be medically monitored.8

PATIENT PREFERENCE IS KEY TO SUCCESSFUL PAIN MANAGEMENT

A patient’s acceptance or rejection of their medication is an important factor determining treatment success. Analgesic drugs have been associated with variable rates of treatment adherence.9 In a
multicentre, open-label, randomised, crossover trial, patients with joint and/or OA pain reported significant preference for sustained-release formulation paracetamol over immediate-release paracetamol across all key study endpoints.10

Adapted from Benson et al.10 In this randomized, open-label, 2-way crossover, phase 4 study of 210 patients with OA in Australia, patient preference for a sustained release paracetamol formulation (2 tablets every 6–8 hours; 3 times daily) or standard paracetamol tablet (2 tablets every 4–6 h; 4 times daily) was compared. The primary endpoint was the proportion of patients preferring the sustained-release versus standard paracetamol tablets for the management of OA pain.

The sustained-release formulation of paracetamol also demonstrated significantly improved joint pain relief versus standard paracetamol (p=0.0019), and higher levels of overall patient satisfaction
(p=0.0003).10

Panadol Osteo is a bi-layer caplet that releases paracetamol in two phases (immediate and sustained-release), providing OA pain relief lasting up to 8 hours.6* When taken three times a day, it provides up to 24 hours of relief.6

In a multi-centre, open-label, randomised, crossover study, patients with joint and/or OA pain were twice as likely to prefer Panadol Osteo over immediate-release paracetamol, reporting greater convenience and satisfaction, a better attitude toward compliance, and a higher Patient Global Assessment of Response to Treatment (PGART) with Panadol Osteo.10

PANADOL OSTEO: Your effective treatment choice for osteoarthritis pain

References

*When used as directed 

1. World Health Organization. Priority Medicines for Europe and the World
Update Report, 2013 (Chapter 6.12: Osteoarthritis) 2013 [Available from:
http://www.who.int/medicines/areas/priority_medicines/Ch6_12Osteo.pdf]

2. The Royal Australian College of General Practitioners. Guideline for the management of knee and hip osteoarthritis. 2nd edn. East Melbourne, Victoria; 2018.

3. National Institute for Health and Care Excellence (NICE). Osteoartritis care and
management in adults (clinical guideline CG177). 2014.

4. GSK Consumer Healthcare. Global Pain Index. GSK Study Conducted by Edelman Intelligence. 2017.

5. American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older P. J Am Geriatr Soc. 2009;57:1331-46.

6. Panadol Osteo. Ermington, NSW, Australia: GlaxoSmithKline Consumer Healthcare Australia; 2018.

7. Graham GG, et al. Inflammopharmacology. 2013;21:201-32.

8. McCrae JC, et al. Br J Clin Pharmacol. 2018.

9. Ortiz M, et al. Aust Fam Physician. 2016;45:321-5

10. Benson M, et al. J Int Med Res. 2009;37:1321-35.

11. Bacon TH, et al., editors. A novel sustained release oral paracetamol formulation. Pharmacokinetics at steady state and relationship to clinical practice in patients with chronic pain. 22nd Annual Scientific Meeting of the Australian Pain Society; 2001.

The 2017 Global Pain Index (GPI) is a recent in-depth study commissioned by GSK Consumer Healthcare to look into attitudes towards physical pain, including OA pain, as well as the impact that
pain has on people’s lives around the world and how physical pain affects them at a macroeconomic level, as well as at a social and emotional level. The purpose of this study is to raise awareness of
what has become a hidden epidemic. The results not only help us to understand the true scale of the issue, but the many impacts that OA pain has on people who live with it.

According to the GPI study, OA pain affects 23% of people surveyed over the age of 18 years in Australia. In over 80% of respondents, OA pain adversely affects quality of life, with the majority of individuals with OA pain reporting an impact on their everyday activities, happiness, and sleep.

83% OF PEOPLE WITH OSTEOARTHRITIS PAIN IN AUSTRALIA SAY THAT OSTEOARTHRITIS PAIN DECREASES THEIR QUALITY OF LIFE 1

 

The GSK Global Pain Index (GPI) 2017 is a global study, commissioned by GSK Consumer Healthcare, looking into attitudes toward physical pain, and the impact that physical and OA pain has on people’s lives around the world. The study included over 19,000 people an used online interviews in 32 countries, including Australia, with people aged 18 and over.4

OSTEOARTHRITIS MANAGEMENT

A holistic approach is recommended for the assessment, diagnosis, and management of OA.2

 

Non-surgical management of knee and/or hip OA2

NSAIDs, non-steroidal anti-inflammatory drug.

 

COMORBIDITIES

Patients with OA are often older and with comorbidities, thereby increasing the likelihood of polypharmacy.5 Older patients take an average of 3–5 medications, increasing the risk of drug–drug
interactions and adverse events.20 Paracetamol has few drug–drug interactions and is generally suitable in polypharmacy.6 Paracetamol has excellent gastrointestinal tolerance7,8 and a very low risk of renal or hepatic side effects.8 However, paracetamol should be used with caution in patients with renal or hepatic impairment.6 As with all medications, patients using long-term, regular paracetamol should also be medically monitored.8

PATIENT PREFERENCE IS KEY TO SUCCESSFUL PAIN MANAGEMENT

A patient’s acceptance or rejection of their medication is an important factor determining treatment success. Analgesic drugs have been associated with variable rates of treatment adherence.9 In a
multicentre, open-label, randomised, crossover trial, patients with joint and/or OA pain reported significant preference for sustained-release formulation paracetamol over immediate-release paracetamol across all key study endpoints.10

Adapted from Benson et al.10 In this randomized, open-label, 2-way crossover, phase 4 study of 210 patients with OA in Australia, patient preference for a sustained release paracetamol formulation (2 tablets every 6–8 hours; 3 times daily) or standard paracetamol tablet (2 tablets every 4–6 h; 4 times daily) was compared. The primary endpoint was the proportion of patients preferring the sustained-release versus standard paracetamol tablets for the management of OA pain.

The sustained-release formulation of paracetamol also demonstrated significantly improved joint pain relief versus standard paracetamol (p=0.0019), and higher levels of overall patient satisfaction
(p=0.0003).10

Panadol Osteo is a bi-layer caplet that releases paracetamol in two phases (immediate and sustained-release), providing OA pain relief lasting up to 8 hours.6* When taken three times a day, it provides up to 24 hours of relief.6

In a multi-centre, open-label, randomised, crossover study, patients with joint and/or OA pain were twice as likely to prefer Panadol Osteo over immediate-release paracetamol, reporting greater convenience and satisfaction, a better attitude toward compliance, and a higher Patient Global Assessment of Response to Treatment (PGART) with Panadol Osteo.10

PANADOL OSTEO: Your effective treatment choice for osteoarthritis pain

 

Download Now

References

*When used as directed 

1. World Health Organization. Priority Medicines for Europe and the World
Update Report, 2013 (Chapter 6.12: Osteoarthritis) 2013 [Available from:
http://www.who.int/medicines/areas/priority_medicines/Ch6_12Osteo.pdf]

2. The Royal Australian College of General Practitioners. Guideline for the management of knee and hip osteoarthritis. 2nd edn. East Melbourne, Victoria; 2018.

3. National Institute for Health and Care Excellence (NICE). Osteoartritis care and
management in adults (clinical guideline CG177). 2014.

4. GSK Consumer Healthcare. Global Pain Index. GSK Study Conducted by Edelman Intelligence. 2017.

5. American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older P. J Am Geriatr Soc. 2009;57:1331-46.

6. Panadol Osteo. Ermington, NSW, Australia: GlaxoSmithKline Consumer Healthcare Australia; 2018.

7. Graham GG, et al. Inflammopharmacology. 2013;21:201-32.

8. McCrae JC, et al. Br J Clin Pharmacol. 2018.

9. Ortiz M, et al. Aust Fam Physician. 2016;45:321-5

10. Benson M, et al. J Int Med Res. 2009;37:1321-35.

11. Bacon TH, et al., editors. A novel sustained release oral paracetamol formulation. Pharmacokinetics at steady state and relationship to clinical practice in patients with chronic pain. 22nd Annual Scientific Meeting of the Australian Pain Society; 2001.

References

*When used as directed 

†Paracetamol has been shown to increase the anticoagulant effect of warfarin and other coumarins.


Related Articles

OA Counselling Guide

3-step approach for pharmacists to assess & identify treatment considerations

Read more

Suitability of paracetamol

Consider key goals, patient characteristics & safety profile

Read more

Panadol Osteo: Formulated with a patented bilayer technology for effective pain relief lasting up to 8 hours*11


Read more

Panadol Osteo Recommendations


Read more

*When used as directed

Related Articles

*When used as directed

Related Articles

*When used as directed